Latest News and Press Releases

SAN DIEGO, April 03, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has received CE Mark approval for its Fantom drug-eluting bioresorbable...

SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold its quarterly briefing call to discuss the Company’s financial results through September...

SAN DIEGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it released final six-month safety data on the complete patient...

SAN DIEGO, Oct. 24, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce the Company’s scheduled presentations during the upcoming Transcatheter...

SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it has submitted an application for CE Marking of its Fantom scaffold,...

SAN DIEGO, May 18, 2016 (GLOBE NEWSWIRE) -- Today at the Paris Course on Revascularization (“EuroPCR”), REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) sponsored a symposium entitled,...

SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- At the Paris Course on Revascularization (“EuroPCR”) being held this week in Paris, France, REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”)...

SAN DIEGO, Feb. 23, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has achieved the targeted enrollment of 110 patients in Cohort B of...

SAN DIEGO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it has enrolled over 200 patients in a clinical study of its Fantom®...

SAN DIEGO, Jan. 07, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present...